Valiant Laboratories Limited

NSE VALIANTLAB.NS

Valiant Laboratories Limited Return on Equity (ROE) for the year ending March 31, 2024: 0.13%

Valiant Laboratories Limited Return on Equity (ROE) is 0.13% for the year ending March 31, 2024, a -99.53% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.
  • Valiant Laboratories Limited Return on Equity (ROE) for the year ending March 31, 2023 was 28.86%, a -25.00% change year over year.
  • Valiant Laboratories Limited Return on Equity (ROE) for the year ending March 31, 2022 was 38.48%, a 11.41% change year over year.
  • Valiant Laboratories Limited Return on Equity (ROE) for the year ending March 31, 2021 was 34.54%.
Key data
Date Return on Equity (ROE) Return on Capital Employed (ROCE) Interest Coverage Ratio Debt to Equity Ratio
Market news
SV Wall Street
NSE: VALIANTLAB.NS

Valiant Laboratories Limited

CEO Mr. Santosh Shantilal Vora
IPO Date Oct. 6, 2023
Location India
Headquarters 104, Udyog Kshetra
Employees 77
Sector Industrials
Industries
Petrochemicals Chemicals & Advanced Materials Cleaning Supplies Drugstores & Retail Pharmacies Non-Alcoholic Beverages Personal Care Pharmaceuticals Plastics
Description

Valiant Laboratories Limited operates as an active pharmaceutical ingredient/bulk drug manufacturing company in India and internationally. The company manufactures paracetamol in various grades, such as Indian/British/European/the United States pharmacopeias for the treatment of headaches, muscle aches, arthritis, back aches, toothaches, cold, and fever. It also offers specialty chemicals. The company was formerly known as Bharat Chemicals and changed its name to Valiant Laboratories Limited in August 2021. The company was founded in 1980 and is based in Mumbai, India. Valiant Laboratories Limited is a subsidiary of Dhanvallabh Ventures LLP.

StockViz Staff

February 2, 2025

Any question? Send us an email